MMSI Stock Intrinsic Value – Merit Medical Systems Secures Five-Year Credit Agreement

☀️Trending News

Merit Medical Systems ($NASDAQ:MMSI), Inc., a leading manufacturer and marketer of disposable medical devices, recently announced that it has secured a five-year senior secured credit agreement. The credit agreement is expected to provide Merit Medical with liquidity and financial flexibility to execute on their strategic objectives, invest in their core business, and take advantage of future growth opportunities. This agreement is expected to enable the company to make long-term investments in its core business and help it compete more effectively in the global markets. It will also help Merit Medical better manage cash flow and working capital.

Share Price

On Thursday, Merit Medical Systems (MERIT) announced that it had secured a five-year credit agreement with several global banking institutions. This new credit agreement will enable the company to expand its operations and provide additional resources for future projects. Following the news, MERIT’s stock opened at $84.9 and closed at $84.3, a 1.2% decrease from the previous closing price of 85.2. The company’s stock has been on a steady decline since the announcement of the new credit agreement, likely due to investors’ concerns about the potential risk associated with such a long-term commitment. The new credit agreement is a positive sign for Merit Medical Systems, as it indicates that the company has access to the necessary capital to continue to function and grow in the coming years. The agreement provides a stable source of funding, which is important for a company that is still in its early stages of growth.

Additionally, it suggests that the company is in good financial health and has the potential to increase its value in the future. Overall, Merit Medical Systems has taken an important step forward with the new credit agreement, providing the company with greater financial security and stability. With this agreement in place, the company should be well positioned to take advantage of future opportunities in order to continue its growth trajectory. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for MMSI. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for MMSI. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for MMSI. More…

Key Ratios Snapshot

Some of the financial key ratios for MMSI are shown below. More…

Analysis – MMSI Stock Intrinsic Value

GoodWhale conducted an analysis of MERIT MEDICAL SYSTEMS’ fundamentals and found that the intrinsic value of the company’s share is approximately $65.9. This value was calculated using GoodWhale’s proprietary Valuation Line. Currently, MERIT MEDICAL SYSTEMS’ stock is trading at $84.3, which is 27.8% above its intrinsic value. This indicates that MERIT MEDICAL SYSTEMS stock is currently overvalued and investors should be cautious of buying the stock at this price. More…

Peers

The company’s products are used in a variety of medical procedures, including cardiovascular, gastrointestinal, urological, and obstetrical/gynecological procedures. The company has a strong competitive position in the medical device market, with a leading market share in many of its product categories.

However, the company faces competition from a number of well-established competitors, including Medeon Biodesign Inc, Pixium Vision SA, and AngioDynamics Inc.

– Medeon Biodesign Inc ($TPEX:6499)

Medeon Biodesign Inc is a medical device company that develops and commercializes products for the treatment of cardiovascular diseases. The company has a market cap of 4.55B and a ROE of -6.27%. Medeon Biodesign Inc’s products are used in the treatment of coronary artery disease, heart failure, and other cardiovascular conditions. The company’s products are sold in over 30 countries worldwide.

– Pixium Vision SA ($OTCPK:PXMVF)

Pixium Vision SA is a French company that designs, develops, and markets bionic vision systems to enable patients who have lost their sight to regain some level of vision. The company’s products include the PRIMA bionic vision system, which consists of an implantable microstimulator and a wearable camera and glasses, and the IRIS II bionic vision system, which consists of an implantable microstimulator and a contact lens. Pixium Vision SA’s products are intended for use in patients with retinitis pigmentosa, macular degeneration, and other degenerative eye diseases.

– AngioDynamics Inc ($NASDAQ:ANGO)

AngioDynamics Inc is a medical device company that designs, manufactures, and sells products used by interventional physicians to treat vascular diseases. The company’s products are used in a variety of procedures, including angioplasty, thrombectomy, ablation, and vascular access. AngioDynamics Inc has a market cap of 549.46M as of 2022, a Return on Equity of -5.11%. The company’s products are used in a variety of procedures, including angioplasty, thrombectomy, ablation, and vascular access. AngioDynamics Inc’s products are sold in over 50 countries worldwide.

Summary

Merit Medical Systems (MERIT) has recently entered into a new five-year senior secured credit agreement. This agreement, which was signed with Bank of America, N.A., expands and replaces the company’s existing credit agreement. In terms of investing analysis, this move is expected to benefit shareholders in the long run as it will provide the company with access to financing that can be used to bolster its future operations and performance. Furthermore, the agreement is expected to improve the company’s capital position, making it more attractive to potential investors and allowing it to take advantage of any potential opportunities that may arise in the market.